… There was no evidence of a difference in metatasis-free survival when enzalutamide and
abiraterone acetate were administered concurrently compared with abiraterone acetate alone (…

… study, the addition of abiraterone acetate plus prednisone to androgen … prostate cancer
(mCSPC). Here, we present long-term survival outcomes and safety of abiraterone acetate plus …

PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease
with current standard-of-care therapies. Homologous recombination repair (HRR) gene …

… improvement in prostate-specific antigen … abiraterone acetate (with prednisone and androgen
deprivation therapy) represents the first androgen annihilation therapy for prostate cancer, …

… Abiraterone acetate plus prednisone and enzalutamide are both used for the treatment of
metastatic castration-resistant prostate cancer. We aimed to determine the best sequence in …

… It can develop into castration-resistant prostate cancer (CRPC) … Abiraterone acetate is
an enzyme inhibitor of CPY17 that … -sensitive prostate cancer, both abiraterone acetate and …

… abiraterone acetate 1000 mg and prednisolone 5 mg (in the abiraterone trial) orally or
abiraterone acetate … orally once a day (in the abiraterone and enzalutamide trial). Patients were …

… from donors not receiving any form of prostate cancer treatment (n = 8) were transferred
to BHI media supplemented with 100 μg/mL of abiraterone acetate (AA) or vehicle (EtOH). …

… to treat metastatic castration-resistant prostate cancer? … -resistant prostate cancer treated
with abiraterone acetate plus … dose combined with abiraterone acetate requires careful …

… antagonist, and abiraterone acetate, a specific … to as abiraterone) [1,2,3,4,5,6,7,8]. The
PREVAIL trial of chemotherapy-naive patients with metastatic castration-resistant prostate cancer (…